Photo
Corps éditorial
Biography
Maelenn is a biostatistician in the Research department of Epicentre since 2019. Currently, she is the operational statistician for the endTB trials. She has international experience in the analysis of epidemiological studies and clinical trials. She has particularly focused on infectious diseases and international health.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Journal Reference:
The Lancet. Respiratory medicine 2025 Jul 16; . doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 07 16
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Journal Reference:
Trials 2021 Sep 25; 22(1); 651. doi: 10.1186/s13063-021-05491-3. Epub 2021 09 25
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Journal Reference:
Trials 2023 Nov 30; 24(1); . doi: 10.1186/s13063-023-07701-6. Epub 2023 11 30
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Journal Reference:
The New England journal of medicine 2025 Jan 30; 392(5); . doi: 10.1056/NEJMoa2400327. Epub 2025 01 29
COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa.
Journal Reference:
PLOS global public health 2025 ; 5(4); . doi: 10.1371/journal.pgph.0004471. Epub 2025 04 23